RecruitingPhase 4ACTRN12615000093583

The impact of Clonidine, a pharmacological treatment for attention deficit hyperactivity disorder (ADHD), on behavioural and brain imaging measures of attention, inhibition and error processing.

A randomised, placebo controlled trial of the effects of Clonidine (200 mcg) on cognitive control and error processing measures (recorded with electroencephalogram (EEG) during behavioural tasks) in a sample of 26 healthy adult males.


Sponsor

Professor Mark Bellgrove

Enrollment

26 participants

Start Date

Feb 3, 2015

Study Type

Interventional

Conditions

Summary

This study assesses the impact of Clonidine a commonly prescribed medication for the treatment of Attention Deficit hyperactivity Disorder (ADHD) on behavioural and brain imaging measures of cognition. Specifically, it measures the impact of Clonidine on key behaviours that are altered in ADHD including, response inhibition, attention and error processing.


Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 40 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing how a medication called Clonidine — often used to treat ADHD — affects attention, self-control, and error processing in healthy adult men. Researchers will use brain scans and computer tests to measure these effects, which could help improve our understanding of how Clonidine works in the brain. You may be eligible if: - You are a healthy adult male between 18 and 40 years old - You have normal or corrected-to-normal vision You may NOT be eligible if: - You have a history of any psychiatric illness - You are currently taking any medications - You are a smoker - You use recreational drugs regularly Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A randomised placebo controlled trial of the effects of Clonidine (200mcg) on cognitive control and error processing measures in healthy adults. Clonidine trade name: Catapress Participants will

A randomised placebo controlled trial of the effects of Clonidine (200mcg) on cognitive control and error processing measures in healthy adults. Clonidine trade name: Catapress Participants will receive each of Clonidine and placebo in capsule form (1 week apart, order of administration randomised). The Experimenter will observe ingestion of the capsule (time 0), participants will commence tasks after 90 minutes has elapsed (onset of drug peak), task will be completed at 180 minutes, observation will then occur for half an hour before completion at 210 minutes.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12615000093583